BACKGROUND: Recently, video-assisted thoracoscopic surgery(VATS) has been accepted as the standard treatment for spontaneous pneumothorax. However, comparatively high recurrent rate and cost-effectiveness are still controversial. The recurrent rate after bullectomy with VATS is reported to be as high as 5-10% whereas it is below 2% in thoracotomy. There is no statistical report on cost-effectiveness in Korean health care system. Material and METHOD: Our retrospective analysis was performed on 173 cases of surgically treated primary spontaneous pneumothorax at Kangbuk Samsung Hospital, Sungkyunkwan University, School of medicine, from January 1997 to July 1999. There were 104 cases VATS and 69 cases of thoracotomy. We analysed the operative indication, gender, operating time, amounts of the staples used, tube drainage, tube stay time, postoperative complications, recurrent rate, operation room cost, and total cost. RESULT: Operation time was 71.3 +/-29.5minutes in VATS group and 141 +/-52minutes in thoracotomy group(P<0.05). The postoperative tube stay and hospital stay are 3.93days and 7.5days in VATS group and 7.0 days and 13.4days in thoracotomy group, respectively(P<0.05, P<0.05). The number of recurrence after the operation in VATS group(6/104, 5.6%) was significantly higher than in thoracotomy group (1/69, 1.4%; P<0.05). The operation room cost was significantly higher in VATS group than in thoracotomy group (won 1,202,192 +/-178,992, won 1,005,669 +/-311,531; P<0.05), but considering the total cost, there was no significant difference between the two groups( won 1,946,110 +/- 487,440, won 1,793,912 +/-308,079; P=0.18). CONCLUSION: Although operative procedure and discharge policy may affect the recurrent rate and cost, there was no benefit of cost-effectiveness in VATS group and recurrent rate was higher in VATS group than in throacotomy group. It would be helpful to set up a prospective trial comparing cost and results of VATS versus minithoracotomy.
Cost-Benefit Analysis ; Delivery of Health Care ; Drainage ; Humans ; Length of Stay ; Pneumothorax* ; Postoperative Complications ; Recurrence ; Retrospective Studies ; Surgical Procedures, Operative ; Thoracic Surgery, Video-Assisted* ; Thoracoscopy ; Thoracotomy*

BACKGROUND: Paraplegia remains unresolved as the most dreaded operative complication with surgical treatment of descending thoracic and thoracoabdominal aortic diseases. In this study, the neuroprotective effect of trimetazidine that has been used clinically for ischemic heart disease was investigated in a rabbit spinal cord ischemia model. MATERIAL AND METHOD: Thirty-three New Zealand white rabbits were randomized as follows: control group undergoing abdominal aortic occlusion but receiving no pharmacologic intervention(Group 1, n=17); TMZ group(Group 2, n=16) receiving 3 mg/kg trimetazidine intravenously before the occlusion of the aorta. Ischemia was induced by clamping the abdominal aorta just distal to the left renal artery for 30 minutes. Neurologic status was assessed at 2, 24, and 48 hours after the operation according to the modified Tarlov scale, then the lumbosacral spinal cord was processed for histopathologic examinations 48 hours after the final assessment. RESULT: The average motor function score was significantly higher in the TMZ group(3.20 +/- 0.77 vs 1.13 +/- 1.25 at 2 hours, 3.50 +/- 0.76 vs 1.45 +/- 1.57 at 24 hours, and 3.91 +/- 0.30 vs 1.86 +/- 1.86 at 48 hours after operation; p value Aorta ; Aorta, Abdominal ; Aortic Diseases ; Constriction ; Ischemia ; Myocardial Ischemia ; Neuroprotective Agents ; Paraplegia ; Rabbits ; Renal Artery ; Spinal Cord Injuries ; Spinal Cord Ischemia* ; Spinal Cord* ; Trimetazidine*

BACKGROUND: Paraplegia remains unresolved as the most dreaded operative complication with surgical treatment of descending thoracic and thoracoabdominal aortic diseases. In this study, the neuroprotective effect of trimetazidine that has been used clinically for ischemic heart disease was investigated in a rabbit spinal cord ischemia model. MATERIAL AND METHOD: Thirty-three New Zealand white rabbits were randomized as follows: control group undergoing abdominal aortic occlusion but receiving no pharmacologic intervention(Group 1, n=17); TMZ group(Group 2, n=16) receiving 3 mg/kg trimetazidine intravenously before the occlusion of the aorta. Ischemia was induced by clamping the abdominal aorta just distal to the left renal artery for 30 minutes. Neurologic status was assessed at 2, 24, and 48 hours after the operation according to the modified Tarlov scale, then the lumbosacral spinal cord was processed for histopathologic examinations 48 hours after the final assessment. RESULT: The average motor function score was significantly higher in the TMZ group(3.20 +/- 0.77 vs 1.13 +/- 1.25 at 2 hours, 3.50 +/- 0.76 vs 1.45 +/- 1.57 at 24 hours, and 3.91 +/- 0.30 vs 1.86 +/- 1.86 at 48 hours after operation; p value Aorta ; Aorta, Abdominal ; Aortic Diseases ; Constriction ; Ischemia ; Myocardial Ischemia ; Neuroprotective Agents ; Paraplegia ; Rabbits ; Renal Artery ; Spinal Cord Injuries ; Spinal Cord Ischemia* ; Spinal Cord* ; Trimetazidine*

OBJECTIVE: This study examined the efficacy and safety of memantine-an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist-in the treatment of moderate-to-severe dementia. METHODS: Forty-four patients with moderate-to-severe dementia received 20 mg of memantine daily for 24 weeks. The primary efficacy variable was measured by the Korean version of Severe Impairment Battery(K-SIB), and the secondary efficacy variables were measured using the Seoul-Activites of Daily Living(S-ADL) and Neuropsychiatric Inventory-Questionnaire(NPI-Q). Neuropsychological assessments were administrated at baseline, 12 weeks, and 24 weeks. Safety parameters were monitored. RESULTS: Of 44 patients recruited, 30 completed the study and 14 dropped out. Memantine-treated patients showed a therapeutic benefit in all efficacy variables ; the K-SIB, S-ADL, and NPI-Q total scores were not significantly different from baseline either at the endpoint(in the analysis of intention-to-treat, with the last observation carried forward, ITT-LOCF) or at week 24(in the analysis of observed cases, OC). The response rates, when "response" was defined as improved or unchanged in the K-SIB or the S-ADL scores, were 43.3 and 50%, respectively(in the analysis of OC). The responders showed significant improvement in the cognitive subdomain of memory function, praxis, visuospatial ability, and orienting to name. Memantine was shown to be tolerable and safe. CONCLUSIONS: Memantine treatment reduced or delayed clinical deterioration in cognition, function, and behavior in patients with moderate-to-severe dementia.
Cognition ; Dementia* ; Humans ; Memantine* ; Memory ; N-Methylaspartate

Rifampicin is a powerful agent for the treatment of pulmonary tuberculosis. However, it may induce several adverse effects, including rare cases of lung toxicity. Here, we report a case of rifampicin-induced interstitial pneumonitis. A 57-year-old woman diagnosed with cerebellar tuberculoma developed progressive dyspnea after the 5th day of anti-tuberculosis medication. Chest X-ray revealed newly developed ground glass opacities on both lower lung fields. Drug-induced pneumonitis was suspected and all anti-tuberculosis medications were halted. Transbronchial lung biopsy was consistent with desquamative interstitial pneumonitis. After clinical improvement, a rechallenge test with each anti-tuberculosis medication was attempted. No primary anti-tuberculosis drug except rifampicin triggered recurrence of symptoms, supporting a diagnosis of rifampicin-induced interstitial pneumonitis. Clinicians should be aware of this rare, but serious, side effect of rifampicin treatment.
Biopsy ; Dyspnea ; Female ; Glass ; Humans ; Lung ; Lung Diseases, Interstitial ; Middle Aged ; Pneumonia ; Recurrence ; Rifampin ; Thorax ; Tuberculoma ; Tuberculosis ; Tuberculosis, Pulmonary